- Company
- Ilaris reattempts reimb for its 13 patients in Korea
- by Eo, Yun-Ho May 23, 2022 06:06am
- ‘Ilaris,’ an ultra-orphan drug indicated for only 13 patients in Korea, is reattempting to be listed for insurance benefit. According to industry sources, Novartis Korea recently submitted an application to receive insurance benefits for its hereditary periodic fever syndrome treatment ‘Ilaris (canakinumab). This is the first attempt
- Company
- Keytruda became a new breakthrough in the tx
- by May 23, 2022 06:06am
- MSD's Keytruda succeeded in applying Hodgkin's lymphoma benefit for the second time as an immuno-cancer drug. Takeda is considered the best option for Hodgkin's lymphoma treatment. It is evaluated as suitable as a new option by proving superiority through comparative clinical trials with Takeda's Adcetris. As of March 1, Keytruda was reimburs
- Company
- Keytruda leads sales for the 9th consecutive quarter
- by Chon, Seung-Hyun May 23, 2022 06:06am
- MDS’s cancer immunotherapy Keytruda has again topped the rank in pharmaceutical sales this year. Its increase in sales has been reduced somewhat due to the price cut disposition that followed Keytruda's reimbursement expansion, still, the drug was able to maintain its lead for the 9th consecutive quarter. Also, new drugs from multinational phar
- Company
- The global competitiveness of new drugs depends on
- by Nho, Byung Chul May 23, 2022 06:06am
- Public opinion on the realization of the preference for new drugs developed in Korea is rising ahead of the announcement of the results of research services on drug prices support policies for innovative pharmaceutical companies in line with the international trade order. The research service, which took place for five months from December
- Company
- COVID-19 exports to Australia↑123 times in a year
- by Kim, Jin-Gu May 23, 2022 06:06am
- In the January-April period, exports of medicines to Australia surged more than 100 times compared to the same period last year-on-year. In the pharmaceutical bio industry, it is interpreted that the moderna vaccine produced by Samsung BioLogics was exported to Australia in earnest, leading to an increase in total exports. Exports to Germany,
- Company
- The standard of Xospata is very disappointing
- by Eo, Yun-Ho May 19, 2022 05:51am
- Insurance benefits for the new leukemia drug Xospata have been applied, but clinics are expressing regret. Acute Myeloid Leukemia (AML) treatment Xospata has been reimbursed since March. Looking at the benefit criteria of this drug, remission-induction therapy is recognized in patients with FLT3 mutant acute myeloid leukemia who are refrac
- Company
- Samsung Bioepis makes ₩199.1 bil in Q1
- by Chon, Seung-Hyun May 19, 2022 05:51am
- Samsung Bioepis is off to a smooth start this year with a sharp rise in its biosimilar sales. According to the Korea Financial Supervisory Service, Samsung Bioepis recorded &8361;199.1 in Q1 sales this year, a 19.4% increase compared to the same quarter of the previous year. Also, the company’s net profit increased 11.5% to &8361;31.9 bill
- Company
- Samsung Bioepis’s Lucentis biosimilar approved in Korea
- by Lee, Seok-Jun May 18, 2022 10:42pm
- Samsung Bioepis became the first company to receive approval for a Lucentis biosimilar in Korea with ‘Amelivu (ranibizumab).’ Lucentis is a treatment developed by Genetech for ophthalmologic diseases such as macular degeneration and macular edema. With Amelivu’s approval, Samsung Bioepis is now approved for a total of 6 biosimilars in Ko
- Company
- Shionogi applies to trademark its COVID-19 treatment
- by Kim, Jin-Gu May 17, 2022 06:02am
- With the domestic trademark application for the COVID-19 treatment that is being jointly developed by Shionogi Pharma and Ildong Pharmaceutical nearing completion, Shionogi Pharma and Ildong Pharmaceutical are speeding up preparations to commercialize its drug in Korea in the second half of this year. According to the Korean Intellectual
- Company
- Pharmaceutical exports fall 19% this year
- by Kim, Jin-Gu May 17, 2022 06:02am
- Pharmaceutical exports from January to April last year were found to have fallen 19% from the same period in the previous year. According to the Korea Customs Service on the 16th, pharmaceutical exports from January to April this year have recorded $2,191,880,000 (approx. &8361;2.81 trillion). This is a 19% decrease from the $2,689,820,000 (
